Almind K, Ambye L, Urhammer S A, Hansen T, Echwald S M, Holst J J, Gromada J, Thorens B, Pedersen O
Steno Diabetes Center, Copenhagen, Denmark.
Diabetologia. 1998 Oct;41(10):1194-8. doi: 10.1007/s001250051051.
The two incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), are insulinotropic factors released from the small intestine to the blood stream in response to oral glucose ingestion. The insulinotropic effect of GLP-1 is maintained in patients with Type II (non-insulin-dependent) diabetes mellitus, whereas, for unknown reasons, the effect of GIP is diminished or lacking. We defined the exon-intron boundaries of the human GIP receptor, made a mutational analysis of the gene and identified two amino acid substitutions, A207 V and E354Q. In an association study of 227 Caucasian Type II diabetic patients and 224 matched glucose tolerant control subjects, the allelic frequency of the A207 V polymorphism was 1.1% in Type II diabetic patients and 0.7% in control subjects (p = 0.48), whereas the allelic frequency of the codon 354 polymorphism was 24.9% in Type II diabetic patients versus 23.2% in control subjects. Interestingly, the glucose tolerant subjects (6% of the population) who were homozygous for the codon 354 variant had on average a 14% decrease in fasting serum C-peptide concentration (p = 0.01) and an 11% decrease in the same variable 30 min after an oral glucose load (p = 0.03) compared with subjects with the wild-type receptor. Investigation of the function of the two GIP receptor variants in Chinese hamster fibroblasts showed, however, that the GIP-induced cAMP formation and the binding of GIP to cells expressing the variant receptors were not different from the findings in cells expressing the wildtype GIP receptor. In conclusion, amino acid variants in the GIP receptor are not associated with random Type II diabetes in patients of Danish Caucasian origin or with altered GIP binding and GIP-induced cAMP production when stably transfected in Chinese hamster fibroblasts. The finding of an association between homozygosity for the codon 354 variant and reduced fasting and post oral glucose tolerance test (OGTT) serum C-peptide concentrations, however, calls for further investigations and could suggest that GIP even in the fasting state regulates the beta-cell secretory response.
两种肠促胰岛素,即葡萄糖依赖性促胰岛素多肽(GIP)和胰高血糖素样肽-1(GLP-1),是在口服葡萄糖后从小肠释放到血流中的促胰岛素因子。GLP-1的促胰岛素作用在II型(非胰岛素依赖型)糖尿病患者中得以维持,而GIP的作用却因不明原因减弱或缺失。我们确定了人类GIP受体的外显子-内含子边界,对该基因进行了突变分析,并鉴定出两个氨基酸替换,即A207V和E354Q。在一项对227名白种人II型糖尿病患者和224名匹配的糖耐量正常对照者的关联研究中,A207V多态性的等位基因频率在II型糖尿病患者中为1.1%,在对照者中为0.7%(p = 0.48),而密码子354多态性的等位基因频率在II型糖尿病患者中为24.9%,对照者中为23.2%。有趣的是,与野生型受体的受试者相比,密码子354变体纯合的糖耐量正常受试者(占人群的6%)空腹血清C肽浓度平均降低了14%(p = 0.01),口服葡萄糖负荷后30分钟同一变量降低了11%(p = 0.03)。然而,对中国仓鼠成纤维细胞中两种GIP受体变体功能的研究表明,GIP诱导的环磷酸腺苷(cAMP)形成以及GIP与表达变体受体的细胞的结合与表达野生型GIP受体的细胞中的发现并无差异。总之,GIP受体中的氨基酸变体与丹麦白种人起源的患者的散发性II型糖尿病无关,也与稳定转染到中国仓鼠成纤维细胞中时GIP结合和GIP诱导的cAMP产生的改变无关。然而,密码子354变体纯合与空腹及口服葡萄糖耐量试验(OGTT)后血清C肽浓度降低之间存在关联这一发现,需要进一步研究,并且可能表明即使在空腹状态下GIP也能调节β细胞的分泌反应。